

GLAXOSMITHKLINE PLC  
Form 6-K  
February 22, 2011

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending February 2011

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

Notifiable Share Interest in Theravance, Inc.

GlaxoSmithKline plc ("GSK") announces that on 18 February 2011 GSK purchased 152,278 shares of Common Stock of Theravance, Inc. ("Theravance") at a price of \$23.70 per share, for a total investment of \$3,608,988.60. These shares were purchased from Theravance pursuant to GSK's right to acquire, on a quarterly basis, sufficient shares of common stock to maintain its ownership percentage in Theravance, taking into account the preceding quarter's net option exercise and equity vesting activity.

GSK's interest in Theravance now comprises 5,902,278 shares of Common Stock and 9,401,499 shares of Class A Common Stock, which together represent approximately 19.01% of Theravance's outstanding capital stock. The calculation is based on a total of 80,503,825 shares of Common Stock outstanding in Theravance. This purchase is disclosable and will be reported under the rules of the Securities and Exchange Commission.

Victoria Whyte  
Company Secretary

21 February 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 21 2011

By: VICTORIA WHYTE  
-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc